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The RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney
disease) criteria were introduced in 2004, defining the
clinical stage of acute kidney injury (AKI) and outcome
measures based on serum creatinine, glomerular filtration
rate, and urine output. However, a growing body of
evidence suggests that these markers are insufficient in
drawing an accurate illustration of kidney injury. Indeed,
mortality and morbidity remain high in AKI, suggesting
that accuracy and speed of patient evaluation are lacking.
A great deal of evidence indicates that neutrophil
gelatinase-associated lipocalin (NGAL) is a sensitive and
specific early marker of various etiological classes of AKI
and would be highly valuable in conjunction with
existing markers of AKI for better classifying renal injury
as well as dysfunction (kidney attack). Improvements
in diagnosis, risk identification, stratification, prognosis,
and therapeutic monitoring will benefit clinical
decision-making in the individualized bundling of
therapies and ongoing patient management. In
particular, kidney protection and AKI prevention may
become feasible if an earlier and more accurate diagnosis
is made for AKI. Here, we discuss the opportunity to
consider whether NGAL is ready for routine clinical use in
a number of etiologies of AKI.tus of clinical routine test? It should be easy and simpleEarly diagnosis of acute kidney injury
In a previous issue of Critical Care, Matsa and colleagues
[1] suggest that, in patients with no kidney disease prior to
admission to the ICU, both plasma (pNGAL) and urinary
(uNGAL) neutrophil gelatinase-associated lipocalin have a
fair predictive value to diagnose the occurrence of acute
kidney injury (AKI) for up to 72 hours. This performanceCorrespondence: cronco@goldnet.it
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sured at serial time points throughout the ICU stay [1].
This commentary, in conjunction with other lines of evi-
dence in the literature, poses the question of whether
NGAL as a biomarker of AKI can be considered ready for
clinical routine use [2]. AKI, also called ‘kidney attack’, is
defined as an abrupt reduction in kidney function because
of multiple causes. Its incidence is increasing in hospital-
ized patients, especially in conditions of critical illness or
aging of the population or both [3-6]. The spectrum of
AKI is a continuum that starts with an increased suscepti-
bility and ends with complete failure of the organ. AKI,
however, is diagnosed only when a significant number of
nephrons are damaged and serum creatinine (sCr) rises
above 0.3 mg/dL or a severe oliguria is present. Unlike sCr
and urine output, kidney status cannot be comprehen-
sively measured by loss of function alone. SCr concentra-
tion may increase slowly, perhaps only following a
substantial decrease in kidney function. SCr is also
influenced by factors such as age, gender, muscle mass,
and nutritional status. AKI can, and should, be diag-
nosed earlier in order to allow organ protection and
prevention of further organ damage. Novel biomarkers
such as NGAL seem to represent a suitable possibility
to accomplish this task.
What is required for a biomarker to achieve the sta-
to measure, should be consistent in repetitive measure-
ment, have a rationale for its use, present threshold
values that are well documented, be correlated with the
presence of illness and with its severity, have a reason-
able cost, and finally be measurable in biological fluids
that are easily achievable. In this case, uNGAL and
pNGAL seem to be both suitable with a small over-
performance of urine testing.
AKI is an important outcome measure that prompts
therapeutic responses and decisions. Hence, early
diagnosis is the key factor for effective prevention andhe licensee has exclusive rights to distribute this article, in any medium, for 12
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markers, even in the absence of creatinine rise, may help
to identify trends or specific values considered thresholds
for the diagnosis. Bagshaw and colleagues [7] demon-
strated that patients who developed worsening AKI had a
higher serum level of pNGAL compared with those whose
AKI did not deteriorate. A systematic review by Haase and
colleagues [8] demonstrated the predictive value of NGAL
for renal replacement therapy (RRT). For pNGAL levels of
greater than 150 ng/mL, the diagnostic odds ratio for
subsequent need of RRT was 12.4.
In extended-criteria kidney donors, NGAL has been
shown to be an early indicator of kidney graft function
and calcineurin inhibitor nephrotoxicity. Ongoing diag-
nostic applications of NGAL include the assessment of
risk, decision-making in single or multiple therapies, and
patient monitoring. In cases of suspected sepsis, Kim and
colleagues [9] demonstrated the sensitivity of NGAL with
sCr in its diagnosis and staging. pNGAL was significantly
better associated than sCr with the renal subscore of the
Sequential Organ Failure Assessment in critically ill
patients with suspected sepsis. Although pNGAL was a
sensitive and early marker of AKI within this cohort, it
was not possible to distinguish AKI patients in the sepsis
cohort, because of the systemic inflammatory nature of
the disease [9].
Patient risk assessment is critical to stratify populations
and make accurate prognoses as well as identify suitable
or harmful therapies for individual patients (theragnos-
tics). This underlines once more the need for the routine
clinical availability of early and accurate prognostic indica-
tors. To test the suitability of NGAL as such a tool, clinical
trials using point-of-care pNGAL and uNGAL testing
should be designed to predict which patients will meet the
criteria for AKI. Today, however, criteria for the diagnosis
of AKI are subject to change, and the sole increase beyond
a given threshold of a biomarker such as NGAL may allow
clinicians not only to suspect a risk for AKI but also to
make a diagnosis of subclinical AKI or non-creatinine-
increase AKI [4-6,10,11].
Elevated NGAL levels have been reported in heart
failure, coronary heart disease, and stroke. Outcome in
heart failure cases is better predicted by renal markers
than cardiac markers, and NGAL has been shown to
correlate with cardiovascular disease (CVD) clinical se-
verity. Some studies have shown NGAL to be an inde-
pendent predictor of major adverse cardiovascular
events and mortality; however, this is not yet conclusive.
But as an independent marker of CVD, it nonetheless
has the potential to offer unique clinical information
[4-6,10,11].
Fast and accurate biomarker assays will significantly im-
prove morbidity and mortality by providing diagnosis in
hours rather than days. This is particularly pertinent inongoing patient management and triage decision-making
in AKI. The readiness of such technology, and the benefit
it confers versus its cost, must be considered.
AKI can have an incidence of up to 7% in the emergency
department. There is a limited applicability of the RIFLE
(Risk, Injury, Failure, Loss, and End-stage kidney disease)
criteria in the emergency setting because of a lack of base-
line sCr measures; therefore, the additive value of NGAL
testing in AKI, and NGAL and brain natriuretic peptide
(BNP) testing in cardiorenal syndrome, becomes remark-
able in clinical judgment accuracy as well as in patient risk
stratification [12].
NGAL testing has the potential to facilitate rapid
decision-making by producing results from small sample
volumes in a matter of seconds. This approach is cur-
rently being tested with point-of-care testing of NGAL
and BNP in the setting of acute fluid resuscitation in
severely burned patients [13]. There is an urgent need to
prove the viability of these techniques in order for them
to be translated into clinical practice.
The next step will be characterized by the feedback to,
and early diagnosis of, AKI made by biomarkers. Can we
respond in a timely fashion? Do we have specific strat-
egies? Before addressing these questions, we must agree
on the fact that a routine use of a test is definitely facilitat-
ing its incorporation in the diagnostic armamentarium of
a disease or a population. Once we agree on this concept,
we will need to recapitulate the pathway that has been
made by BNP for heart failure and troponins for acute
coronary syndromes.
The need to introduce novel independent biomarkers of
AKI into the clinical setting is crucial for earlier diagnosis
and improved risk assessment. A parallel problem is the
poor understanding of pathophysiology of AKI, which
would be improved by the comprehensive characterization
of the molecular pathways involved in the propagation of
kidney injury.
Some etiological areas may benefit from further work or
confirmatory trials in specific populations [1]. However,
the development of individual criteria and decision-
making frameworks for the etiological variants of AKI is
necessary to encompass the variety of factors that can
influence clinical decisions. This exercise demands the
consensus of experts regarding a proposed protocol for
the inclusion of NGAL within evolved RIFLE criteria. At
the same time, routine clinical utilization of injury
biomarkers will probably be the solution for real advance-
ment in this area.Abbreviations
BNP: Brain natriuretic peptide; CVD: Cardiovascular disease; NGAL: Neutrophil
gelatinase-associated lipocalin; pNGAL: Plasma neutrophil gelatinase-associated
lipocalin; RIFLE: Risk, Injury, Failure, Loss, and End-stage kidney disease;
RRT: Renal replacement therapy; sCr: Serum creatinine; uNGAL: Urinary
neutrophil gelatinase-associated lipocalin.
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